Quick Answer
Vistagen Therapeutics, Inc. reported R&D Expense of $39.38 million for fiscal year 2025.
Vistagen Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $39.38M | +96.7% |
| 2024 | $20.02M | -54.9% |
| 2023 | $44.38M | +25.3% |
| 2022 | $35.41M | +196.9% |
| 2021 | $11.93M | -10.8% |
| 2020 | $13.37M | -21.8% |
| 2019 | $17.10M | +120.3% |
| 2018 | $7.76M | +49.2% |
| 2017 | $5.20M | +32.4% |
| 2016 | $3.93M | +61.6% |
| 2015 | $2.43M | -29.1% |
| 2013 | $3.43M | -36.3% |
| 2012 | $5.39M | +46.5% |
| 2011 | $3.68M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $14.22M | +25.8% | -10.6% |
| September 30, 2025 | $15.91M | +55.8% | +36.3% |
| June 30, 2025 | $11.68M | +52.7% | +3.3% |
| December 31, 2024 | $11.30M | +149.2% | +10.7% |
| September 30, 2024 | $10.21M | +165.3% | +33.6% |
| June 30, 2024 | $7.65M | +82.2% | +68.6% |
| December 31, 2023 | $4.54M | -33.8% | +17.8% |
| September 30, 2023 | $3.85M | -70.1% | -8.2% |
- Vistagen Therapeutics, Inc. showed an increase of +96.7% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, Vistagen Therapeutics, Inc.’s r&d expense has grown by 970.5% (from $3.68 million to $39.38 million).
- The most recent figure is from Vistagen Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: